Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;13(1):31-49.
doi: 10.2217/fon-2016-0355. Epub 2016 Sep 6.

Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma

Anna M Czarnecka  1 , Paweł Sobczuk  1   2 , Jan Korniluk  1 , Marta Spychalska  1   2   3 , Krzysztof Bogusz  1   4 , Anna Owczarek  1   2   5 , Anna Brodziak  1   2 , Dominika Labochka  1   2 , Barbara Moszczuk  1   2 , Cezary Szczylik  1
Affiliations

Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma

Anna M Czarnecka et al. Future Oncol. 2017 Jan.

Abstract

Aim: The study aim was to evaluate progression-free survival (PFS) and overall survival (OS) in patients with metastatic clear cell renal cell carcinoma on sunitinib (SU) and SU-everolimus treatment.

Patients & methods: After 7 years of enrollment and 9 years of follow-up, 193 consecutively presenting patients (151 men and 42 women) were treated.

Results: A total of 157 patients (81.3%) died and 36 patients (18.7%) survived. Median PFS in 193 SU-treated patients was 14.7 months and OS was 28.8 months. Median PFS was 13.98 months and median OS was 26.67 months in 175 patients treated with SU only or on SU-everolimus.

Conclusion: The development of SU-induced hypothyroidism, hypertension, neutropenia and edema was a significant predictive and prognostic factor.

Keywords: EVE; SU; everolimus; prediction; prognosis; renal cancer; sunitinib; survival.

PubMed Disclaimer

MeSH terms

LinkOut - more resources